Bryn Mawr Trust CO Exelixis, Inc. Transaction History

Bryn Mawr Trust CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 28, 2025	BUY	$36.22 - $46.25 $398 - $508	11 Added 1.42%	786 $32,000
Q2 2025 Jul 28, 2025	SELL	$34.13 - $46.26 $170 - $231	-5 Reduced 0.64%	775 $34,000
Q1 2025 May 08, 2025	SELL	$32.38 - $39.16 $453 - $548	-14 Reduced 1.76%	780 $28,000
Q4 2024 Jan 28, 2025	BUY	$25.39 - $36.46 $2,285 - $3,281	90 Added 12.78%	794 $26,000
Q3 2024 Nov 25, 2024	BUY	$21.96 - $27.6 $15,459 - $19,430	704 New	704 $18,000

694

257M

1.5M

1.71M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $13.4B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Bryn Mawr Trust CO, based on Form 13F filings with the SEC.

Stay updated on Bryn Mawr Trust CO with notifications on news.